Villere ST Denis J & Co. LLC Sells 10,866 Shares of Pfizer Inc. (NYSE:PFE)



Villere ST Denis J & Co. LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239,784 shares of the biopharmaceutical company’s stock after selling 10,866 during the period. Villere ST Denis J & Co. LLC’s holdings in Pfizer were worth $12,413,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $290,000. PYA Waltman Capital LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $31,000. Econ Financial Services Corp bought a new position in shares of Pfizer during the fourth quarter worth approximately $31,000. Rinkey Investments bought a new position in shares of Pfizer during the fourth quarter worth approximately $32,000. Finally, Bivin & Associates Inc. bought a new position in shares of Pfizer during the fourth quarter worth approximately $37,000. 66.50% of the stock is owned by hedge funds and other institutional investors.

Shares of PFE opened at $52.31 on Friday. The company has a market capitalization of $293.51 billion, a PE ratio of 12.00, a PEG ratio of 0.63 and a beta of 0.76. Pfizer Inc. has a 12 month low of $38.93 and a 12 month high of $61.71. The stock’s 50-day moving average price is $50.66 and its two-hundred day moving average price is $52.15. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The company had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 earnings per share. Equities research analysts predict that Pfizer Inc. will post 6.61 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio is 36.70%.

A number of equities analysts have commented on the company. Citigroup raised their objective price on Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 5th. Berenberg Bank set a $50.00 price objective on Pfizer in a research note on Friday, May 27th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Barclays set a $52.00 price target on Pfizer in a research note on Monday, June 27th. Finally, SVB Leerink initiated coverage on Pfizer in a research note on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price target on the stock. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $57.26.

In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock worth $2,075,003 over the last three months. 0.05% of the stock is owned by company insiders.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment